Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures (original) (raw)

• Eng J, Kleinman WA, Singh L, Singh G, Raufman JP . Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402–7405.
  CAS PubMed Google Scholar
• Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)- amide receptor of insulin-secreting beta-cells. J Biol Chem 1993; 268: 19650–19655.
  PubMed Google Scholar
• Thorens B . Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992; 89: 8641–8645.
  Article CAS Google Scholar
• Chen YE, Drucker DJ . Tissue specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 1997; 272: 4108–4115.
  Article CAS Google Scholar
• Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 2001; 53: 260–267.
  Article CAS Google Scholar
• Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999; 48: 1026–1034.
  Article CAS Google Scholar
• Drucker DJ . Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929–2940.
  Article CAS Google Scholar
• Holz GG, Chepurny OG . Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 2003; 10: 2471–2483.
  Article CAS Google Scholar
• Nauck MA . Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004; 36: 852–858.
  Article CAS Google Scholar
• Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628–2635.
  Article CAS Google Scholar
• Defronzo RA, Ratner RE, Han J, Kim D, Fineman MS, Baron AD . Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092–1100.
  Article CAS Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes mellitus treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083–1091.
  Article CAS Google Scholar
• Eng J, Gutterman V, Nicolis C . Exendin(9–39)amide inhibits the insulin secretagogue activity of exendin 4 and GLP-1 but enhances that of glucagon in dogs. Digestion 1993; 54: 354–367.
  Article Google Scholar
• Mojsov S, Weir GC, Habener JF . Insulinotropin: glucagon-like peptide 1 (7–37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987; 79: 616–619.
  Article CAS Google Scholar
• Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082–3089.
  Article CAS Google Scholar
• Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173–181.
  Article CAS Google Scholar
• Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53: 2397–2403.
  Article CAS Google Scholar
• Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD et al. Exenatide (exendin-4) improves insulin sensitivity and _β_-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005; 146: 2069–2076.
  Article CAS Google Scholar
• Nielsen LL, Young AA, Parkes D . Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77–88.
  Article CAS Google Scholar
• Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M et al. Central administration of GLP-1 (7–36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271: R848–R856.
  CAS PubMed Google Scholar
• Van Dijk G, Thiele TE, Seeley RJ, Woods SC, Bernstein IL . Glucagon-like peptide-1 and satiety. Nature 1997; 385: 214.
  Article CAS Google Scholar
• Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K et al. A role for glucagon-like peptide-1 in central regulation of feeding. Nature 1996; 379: 69–72.
  Article CAS Google Scholar
• Van Dijk G, Thiele TE, Donahey JC, Campfield LA, Smith FJ, Burn P et al. Central infusions of leptin and GLP-1-(7–36) amide differentially stimulate c-FLI in the rat brain. Am J Physiol 1996; 271: R1096–R1100.
  CAS PubMed Google Scholar
• Larsen PJ, Vrang N, Tang-Christensen M . Central pre-proglucagon derived peptides: opportunities for treatment of obesity. Curr Pharm Des 2003; 9: 1373–1382.
  Article CAS Google Scholar
• Navarro M, Rodriguez de Fonseca F, Alvarez E, Chowen JA, Zueco JA, Gomez R et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 1996; 67: 1982–1991.
  Article CAS Google Scholar
• Al-Barazanji KA, Arch JR, Buckingham RE, Tadayyon M . Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes Res 2000; 8: 317–323.
  Article CAS Google Scholar
• Rodriquez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O et al. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 2000; 49: 709–717.
  Article CAS Google Scholar
• Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141: 1936–1941.
  Article CAS Google Scholar
• Aziz A, Anderson GH . Exendin-4, a GLP-1 receptor agonist, interacts with proteins and their products to suppress food intake in rats. J Nutr 2003; 133: 2326–2330.
  Article CAS Google Scholar
• Peters CT, Choi YH, Brubaker PL, Anderson PL . A glucagon-like peptide receptor agonist and an antagonist modify macronutrient selection by rats. J Nutr 2001; 131: 2164–2170.
  Article CAS Google Scholar
• Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL . Peripheral exendin-4 and peptide YY (3–36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005; 146: 3748–3756.
  Article CAS Google Scholar
• Wang T, Edwards GL, Baile CA . Glucagon-like peptide-1 (7–36) amide administered into the third cerebroventricle inhibits water intake in rats. Proc Soc Exp Biol Med 1998; 219: 85–91.
  Article CAS Google Scholar
• Thiele TE, Van Dijk G, Campfield LA, Smith FJ, Burn P, Woods SC et al. Central infusion of GLP-1, but not leptin, produces conditioned taste aversion in rats. Am J Physiol Regul Integr Comp Physiol 1997; 272: R726–R730.
  Article CAS Google Scholar
• Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC et al. The role of CNS glucagons-like peptide-1 (7–36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 2000; 20: 1616–1621.
  Article CAS Google Scholar
• Takeda N, Hasegawa S, Morita M, Matsunaga T . Pica in rats is analogous to emesis: an animal model in emesis research. Pharmacol Biochem Behav 1993; 45: 817–821.
  Article CAS Google Scholar
• Mack CM, Wilson JK, Young A, Parkes DG . Effect of systemic 28-day exposure to exenatide (synthetic exendin-4) on food intake and body weight in high fat-fed rats. Diabetes 2004; 53 (Suppl 2): A409.
  Google Scholar
• Moore C, Jodka C, Hoyt J, Young A, Sams-Dodd F . Chronic administration of exenatide (synthetic exendin-4) reduces body weight and improves glycemic control in C57BL/6J mice fed a high fat diet. Diabetes 2003; 52 (Suppl 1): A389.
  Google Scholar
• Smith BK, Andrews K, West DB . Macronutrient diet selection in thirteen mouse strains. Am J Physiol Regul Integr Comp Physiol 2000; 278: R797–R805.
  Article CAS Google Scholar
• Cuniff P (ed). Total Fat, Soxhlet Extraction. AOAC International, 960.39 Fat (Crude) or Ether Extract in Meat (Modified), Offical Methods of Analysis, Vol. 2, 16th edn. AOAC International: Gaithersburg, MD, 1995.
  Google Scholar
• AOAC International. Protein (N X 6.25) Dumas Method. Official Methods of Analysis of AOAC International, Official Methods 968.06 and 992.15. (Modified) 17th edn., AOAC International: Gaithersburg, MD, USA, 2000.
• Hiles R, Carpenter T, Serota D, Schafer K, Ross P, Nelson D et al. Exenatide does not cause pancreatic tumors or malignancies in rats and mice following a 2-year period of exposure. Diabetes 2004; 53 (Suppl 2): A380.
  Google Scholar
• Blonde L, Han J, Mac S, Poon T Taylor K, Kim D . Exenatide (exendin-4) reduced A1C and weight over 82 weeks in overweight patients with type 2 diabetes. Diabetes 2005; 54 (Suppl 1): A118.
  Google Scholar
• Fineman M, Young A, Gaines E, Prickett K . Dose-response for postprandial glucose-lowering effect of synthetic exendin-4 (AC2993) in subjects with type 2 diabetes. Diabetes 200l; 49 (Suppl 1): A106.
  Google Scholar
• Baron A, Fineman M, Young A, Gaines E, Prickett K . Synthetic exendin-4 (AC2993) reduces post-prandial glycemia, glucagon levels and slows gastric emptying in subjects with type 2 diabetes. Diabetologia 2000; 43 (Suppl 1): A190.
  Google Scholar
• Baggio LL, Huang Q, Brown TJ, Drucker DD . Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004; 127: 546–558.
  Article CAS Google Scholar
• Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155–E161.
  Article CAS Google Scholar
• Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A . The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001; 25: 781–792.
  Article CAS Google Scholar
• Kendall DM, Kim D, Poon T, Han J, Schnabel C, Fineman M et al. Improvement in cardiovascular risk factors accompanied sustained effects on glycaemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 weeks. Diabetes 2005; 54 (Suppl 1): A4–A5.
  Google Scholar
• Kinzig KP, D'Alessio DA, Seeley RJ . The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 2002; 22: 10470–10476.
  Article CAS Google Scholar
• McMahon LR, Wellman PJ . PVN infusion of GLP-1-(7–36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol 1998; 274: R23–R29.
  CAS PubMed Google Scholar